Table 4.

Cox univariate analysis outcomes by toxicity type for irAE CTCAE grades 1–2 or grade 1–4 versus grade 0

Toxicity type	HR (95% CI)
	RFS	OS
Any irAE grades 1–2	0.60 (0.52 to 0.90), p=0.006	0.71 (0.49 to 1.02), p=0.065
Any irAE grades 1–4	0.71 (0.55 to 0.93), p=0.011	0.82 (0.58 to 1.17), p=0.270
Rash grades 1–2	0.75 (0.62 to 0.90), p=0.002	0.70 (0.55 to 0.89), p=0.004
Rash grades 1–4	0.77 (0.65 to 0.92), p=0.004	0.74 (0.59 to 0.94), p=0.012
Endo grades 1–2	0.75 (0.61 to 0.92), p=0.005	0.76 (0.58 to 0.99), p=0.045
Endo grades 1–4	0.79 (0.65 to 0.97), p=0.015	0.84 (0.65 to 1.08), p=0.168
Endo and rash grades 1–2	0.65 (0.53 to 0.78), p<0.001	0.63 (0.48 to 0.81), p<0.001
Endo and rash grades 1–4	0.73 (0.57 to 0.92), p=0.009	0.73 (0.57 to 0.92), p<0.001
GI grades 1–2	0.87 (.72 to 1.05), p=0.137	0.88 (0.69 to 1.13), p=0.305
GI grades 1–4	0.88 (0.74 to 1.06), p=0.171	0.94 (0.74 to 1.18), p=0.590

irAE, immune-related adverse event; OS, overall survival; RFS, relapse-free survival.